New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
PR Newswire•11/11/2026•09:45 ET
2
Key Highlights
- ➤Taltz plus Zepbound achieved ACR50 in 43.7% at Week 52 versus 15.7% with Taltz alone
- ➤39.2% achieved ACR50 plus 10% weight reduction versus 1.7% with Taltz alone
- ➤85.7% achieved at least 10% weight reduction versus 6.7% with Taltz alone
- ➤Combination therapy improved metabolic measures including BMI, blood pressure, glucose and cholesterol
- ➤271 participants were randomized in the 52-week Phase 3b TOGETHER-PsA trial
Expert Statements
Mark Genovese, M.D., Senior vice president of Lilly Immunology development
“It's remarkable to see the durability of efficacy and breadth of outcomes with Taltz and Zepbound at one year in measures that matter most to patients with psoriatic arthritis and obesity or overweight, from improvements in disease control to physical function and fatigue. Data from TOGETHER-PsA continue to evolve our understanding of immunometabolic health and show what may be possible for patients when these chronic conditions are treated together to address the combined disease burden.”
Philip Mease, M.D., Director of Rheumatology Research, Swedish Medical Center; Clinical Professor at the University of Washington, Seattle; TOGETHER-PsA study author
“For people living with psoriatic arthritis and obesity or overweight, achieving meaningful disease control can be especially challenging. This makes the improvements seen in rigorous measures of PsA disease activity through Week 52 in the Taltz and Zepbound treatment arm particularly notable. When paired with metabolic improvements and other outcomes impacting patients' daily lives, these findings reinforce why considering the combined disease burden of PsA and obesity matters when caring for patients with both conditions.”
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity PR Newswire
Nearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study
Get started
Create a free account to read the full story.